Sartorius AG (SARTF) Stock
Sartorius AG engages in the provision of solutions for biopharmaceutical research. It operates through following divisions: Bioprocess Solutions (BPS), and Lab Products and Service (LPS).
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Sartorius AG
Sartorius AG engages in the provision of solutions for biopharmaceutical research. It operates through following divisions: Bioprocess Solutions (BPS), and Lab Products and Service (LPS). The Bioprocess Solutions division focuses on single-use solutions, helps customers manufacture biotech medications and vaccines safely and efficiently. The Lab Products and services division serves the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The company was founded by Florence Sartorius, Sr. in 1870 and is headquartered in Goettingen, Germany.
Sartorius AG is headquartered in DE.
Sartorius AG (SARTF) stock trades at $212.80 with a market capitalization of $14.69B. The stock is valued at a price-to-earnings (P/E) ratio of 94.17, price-to-book of 5.60, price-to-sales of 4.30. Over the past 52 weeks the stock has ranged between $181.58 and $227.00, and currently trades 6.3% below its 52-week high. It pays a dividend yielding 0.39%.
On profitability, Sartorius AG generates a return on equity (ROE) of 6.05%, return on capital employed of 7.57%, an operating margin of 16.52%, a net profit margin of 4.58%.
Official website: www.sartorius.com